BiotechTube
Spotlight Medical

Spotlight Medical

Paris, France· Est.
spotlightmedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.8M

Overview

Spotlight Medical is a Paris-based, AI-powered diagnostics company focused on precision oncology. Leveraging decades of patient data and multimodal biological information, it builds prognostic tests to identify which cancer patients are at high or low risk of relapse, thereby guiding more tailored treatment decisions. The company has validated its first assay in breast cancer, secured seed funding, and is building a team to advance its platform. Its core value proposition is reducing overtreatment and side effects while improving cure rates through data-driven clinical tools.

Oncology

Technology Platform

AI/ML platform that analyzes multimodal biological information (e.g., digitized histopathology images, clinicopathologic data) from patient tumors to predict prognosis and optimize treatment selection.

Funding History

1
Total raised:$2.8M
Seed$2.8M

Opportunities

The global shift towards precision oncology and value-based care creates a large market for tools that reduce overtreatment.
Spotlight's AI-based assay, using standard pathology slides, offers a potentially more accessible and cost-effective alternative to complex genomic tests.
Success in breast cancer provides a blueprint for expanding into other major cancers with similar prognostic challenges.

Risk Factors

Key risks include navigating complex regulatory pathways for AI-based medical software and securing reimbursement from healthcare payers.
Clinical adoption may be slow due to market conservatism and the need for robust prospective utility data.
The company also faces intense competition from both startups and established diagnostics giants in the AI-digital pathology space.

Competitive Landscape

Spotlight Medical competes in the AI-powered digital pathology and prognostic testing market. Direct competitors include companies like Paige, PathAI, and Owkin, which also develop AI models for oncology. In breast cancer specifically, it challenges established genomic prognostic tests (e.g., Oncotype DX, MammaPrint). Its differentiation lies in a focused assay that identifies low-risk patients within clinically high-risk groups using standard H&E slides.

More companies in AI / Machine Learning →More companies in France →